解离人和小鼠肿瘤组织样品用于单细胞 RNA 测序
August 16th, 2024
3.4K views
该方案概述了快速解离人和小鼠肿瘤样品以进行单细胞 RNA 测序的程序。
我们的研究范围是研究标准护理免疫疗法的反应或耐药机制。我们的实验室正在努力了解是什么推动了针对肿瘤的成功免疫反应，以及我们是否能够确定这些治疗的预测因素以找到可以克服耐药性的靶点。近年来最大的进步是单细胞 RNA 测序技术的开发和整合。
它们使我们能够实时、无偏见地系统地研究单个细胞中的分子特征，这有助于剖析这些复杂且不断发展的肿瘤生态系统。虽然许多临床前模型被用于研究对免疫疗法的反应机制，但我们仍然不知道对人类免疫很重要的免疫决定因素。实时处理和分析患者样本对于我们研究给定肿瘤内所有细胞区室的能力至关重要。
使用无偏倚的基因组和转录组学技术，我们的实验室发现抗原呈递机制的缺陷与黑色素瘤的免疫治疗耐药性有关。最近，使用单细胞方法，我们发现了独特的 T 细胞状态和髓样细胞极性分别与黑色素瘤和头颈癌的患者预后相关。我们协议的最大优势在于它的简单性。
这是一种通用方案，可在短时间内将小型和大型肿瘤标本从多种类型的癌症中解离，最终产生高活力的单细胞悬液。
概述
该协议概述了快速分离人类和小鼠肿瘤样本用于单细胞RNA测序的程序。这项技术对于理解肿瘤的免疫反应和识别治疗耐药的预测因素至关重要。
关键研究组成部分
科学领域
- 神经科学
- 免疫学
- 单细胞分析
背景
- 理解对免疫治疗的反应或耐药机制。
- 患者样本的实时处理和分析的重要性。
- 单细胞RNA测序技术的发展。
- 需要研究肿瘤内的细胞区室。
研究目的
- 研究对肿瘤的免疫反应。
- 识别治疗成功的预测因子。
- 克服对标准免疫治疗的耐药性。
所用方法
- 单细胞RNA测序
- 肿瘤样本的快速分离
- 分子特征的实时分析
- 肿瘤生态系统的研究
主要结果
- 对免疫反应机制的洞察。
- 关键免疫学决定因素的识别。
- 对肿瘤微环境的更深入理解。
- 克服治疗耐药性的潜在目标。
结论
- 单细胞RNA测序对肿瘤分析至关重要。
- 实时处理有助于理解复杂的肿瘤。
- 未来研究可以集中于识别的治疗预测因子。
常见问题
什么是单细胞RNA测序？
单细胞RNA测序是一种能够在单个细胞水平分析基因表达的技术，为细胞异质性提供洞察。
为什么快速分离肿瘤样本很重要？
快速分离保留了细胞的完整性，并允许及时分析其分子特征，这对于理解肿瘤生物学至关重要。
这项研究如何为免疫治疗研究做出贡献？
这项研究有助于识别免疫反应和耐药性的预测因子，这可以为更有效的免疫治疗策略的开发提供信息。
研究人类免疫力有哪些挑战？
挑战包括人类免疫反应的复杂性和对患者衍生样本的实时分析需求。
肿瘤分析有哪些进展？
最近的进展包括单细胞RNA测序技术的整合，这允许对肿瘤生态系统进行无偏分析。
理解肿瘤生态系统有什么意义？
理解肿瘤生态系统对于识别不同细胞类型如何相互作用并对肿瘤生长和对治疗的反应做出贡献至关重要。
Executive Industry Relevance
Rapid and universal dissociation of human and mouse tumor tissues is a critical enabler for single-cell RNA sequencing (scRNAseq) pipelines in immuno-oncology discovery. High-viability single-cell suspensions directly impact the fidelity of downstream molecular profiling, supporting robust target validation and mechanistic de-risking. This protocol addresses a key inflection point in translational research by ensuring sample quality for high-resolution cellular and immune repertoire analysis.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of tumor microenvironment heterogeneity at single-cell resolution.
- Supports identification of immune and tumor cell states linked to therapy response or resistance.
- Facilitates mechanistic de-risking by preserving sensitive cell populations and minimizing stress-induced artifacts.
- Improves predictive confidence in target selection through high-quality cellular readouts.
Screening & Assay Development
- Delivers validated, viable single-cell suspensions for scRNAseq and multi-omic assays.
- Standardizes sample preparation across tumor types and specimen sizes, including low-input biopsies.
- Reduces cross-contamination and ambient RNA artifacts, enhancing assay reproducibility.
- Enables scalable preparation for high-throughput screening of tumor and immune cell phenotypes.
Translational & Preclinical Research
- Aligns dissociation outputs with translational biomarker discovery and immune repertoire profiling.
- Maintains continuity from patient-derived samples to preclinical model validation.
- Supports risk-adjusted advancement by providing high-fidelity data for cross-species comparison.
- Enables identification of clinically relevant cellular programs and resistance mechanisms.
Pipeline & Workflow Integration
This dissociation protocol is positioned at the interface of tissue acquisition and single-cell molecular profiling, bridging early discovery and translational research workflows.
- Discovery Biology: Provides high-quality inputs for hypothesis testing and pathway analysis in tumor immunology.
- Screening: Ensures reproducible, quantitative single-cell suspensions for downstream scRNAseq and CITEseq assays.
- Analytics: Delivers robust cell viability and concentration metrics to support comparative analyses across conditions.
- Translational Research: Enables direct linkage of patient-derived data to preclinical model systems for biomarker validation.
- Enterprise Reuse: Offers a universal, adaptable protocol suitable for diverse tumor types and research settings.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in immune-oncology discovery.
- Operational Value: Streamlines sample preparation with standardized, rapid workflows and high viability outputs.
- Strategic Value: Improves go/no-go decision quality by enabling reliable single-cell data generation.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of immunotherapy targets and biomarkers.
Implementation Considerations
- Requires expertise in tissue handling, enzymatic digestion, and single-cell assay preparation.
- Needs access to cell counters, magnetic separators, and biosafety infrastructure.
- Demands cross-team standardization for reproducibility across tumor types and input sizes.
- Adaptable to both human and murine samples, including small biopsies and large resections.
- Sample viability and stress response must be monitored to ensure data quality.
Biopharma FAQs
Why does null hypothesis testing matter for scRNAseq-based target validation?
Null hypothesis testing in scRNAseq studies enables teams to rigorously assess whether observed cellular heterogeneity or immune states are statistically significant, supporting robust target validation and reducing false discovery risk in immuno-oncology pipelines.
How does independent variable isolation fit into tumor dissociation workflows?
Isolating variables such as tissue type, dissociation time, and enzymatic conditions ensures that differences in single-cell outputs reflect true biological variation rather than technical artifacts, strengthening discovery-stage confidence.
What do quantitative dependent variable measurements enable in this protocol?
Accurate measurement of cell viability, concentration, and live/dead ratios enables teams to benchmark sample quality, optimize protocol parameters, and ensure reliable downstream scRNAseq data generation.
Why are replication requirements critical for cross-functional collaboration?
Replication of dissociation and single-cell preparation steps across tumor types and input sizes ensures reproducibility, enabling cross-functional teams to compare results and integrate findings across discovery and translational research.
What statistical analysis capabilities are required before scRNAseq implementation?
Teams must be equipped to analyze cell viability distributions, assess batch effects, and validate that sample preparation does not introduce confounding variables, ensuring high-confidence interpretation of single-cell data for portfolio decisions.
